Rodman & Renshaw Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
Rodman & Renshaw initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.
Rodman & Renshaw initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.